Day: February 11, 2026

Atos, with UEFA Futsal EURO™ 2026, Successfully Completes its First Full Cycle of UEFA Men’s National Team Football Competitions as a Proud Partner

Written by Customer Service on February 11, 2026. Posted in Public Companies.

Press Release Atos, with UEFA Futsal EURO™ 2026, Successfully Completes its First Full Cycle of UEFA Men’s National Team Football Competitions as a Proud Partner Paris, France – February 11, 2026 – Atos, a global leader in AI-driven digital transformation, and the “Official Information Technology Partner” of UEFA Men’s National Team Football, is proud to announce it has successfully supported the delivery of UEFA Futsal EURO™ 2026 that just took place in Latvia, Lithuania and Slovenia. Running until 7 February, this major international event highlighted both Atos’ long-standing commitment to UEFA and the extraordinary momentum futsal is gaining worldwide. Futsal is a sport experiencing rapid growth across Europe and worldwide. Recent data confirms that futsal is not only growing, but also accelerating across all...

Logansport Financial Corp. Reports Earnings for the Three and Twelve Months Ended December 31, 2025

Written by Customer Service on February 11, 2026. Posted in Earnings Releases And Operating Results.

LOGANSPORT, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) — Logansport Financial Corp., (OTCBB: LOGN), parent company of Logansport Savings Bank, reported net earnings for the three and twelve months ended December 31, 2025. Net earnings for the three months ended December 31, 2025 totaled $453,000, compared to the $445,000 in net earnings reported for the three months ended December 31, 2024. Net earnings for the year ended December 31, 2025 totaled $1,763,000, compared to the $1,254,000 reported for the year ended December 31, 2024. Earnings per share was $2.88 for December 31, 2025, compared to $2.05 for December 31, 2024. Return on Assets finished the year at 0.664% for 2025 compared to 0.475% for 2024. The Return on Equity finished the year at 7.76% for December 31, 2025, compared to 6.14% for December 31, 2024. The statements contained...

Century Announces Filing of Third Quarter Financial Results and Management Discussion and Analysis for the Nine Months Ended December 31, 2025

Written by Customer Service on February 11, 2026. Posted in Earnings Releases And Operating Results.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION INTHE UNITED STATES OR TO U.S. NEWS AGENCIES HONG KONG, Feb. 11, 2026 (GLOBE NEWSWIRE) — Century Global Commodities Corporation (“Century” or the “Company”) (TSX: CNT) is pleased to announce that it has filed its condensed consolidated interim financial statements for the third fiscal quarter ended December 31, 2025 and the related management discussion and analysis (“MD&A”). Copies of these documents are available under Century’s SEDAR+ profile at http://www.sedarplus.ca and will also be posted on Century’s website at www.centuryglobal.ca. As of December 31, 2025, the Company had unrestricted free cash, bank deposits and marketable securities totaling $2.3 million (March 31, 2025: $4.2 million) and a net working capital* of $5.2 million (March 31, 2025: $6.0 million), which is adequate...

Comstock Inc. Featured on Water Tower Research Small-Cap Spotlight Podcast

Written by Customer Service on February 11, 2026. Posted in Public Companies.

VIRGINIA CITY, Nev., Feb. 11, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” or the “Company”) and its subsidiary, Comstock Metals LLC (“Comstock Metals”), a leader in the responsible recycling of end-of-life solar panels and the only certified, zero-landfill solar recycling solution in North America, today announced that Executive Chairman and Chief Executive Officer Corrado De Gasperis was featured on the Water Tower Research Small-Cap Spotlight Podcast. The Small-Cap Spotlight Podcast explores a deeper analysis of the end-of-life solar panel dilemma and the innovations required to both handle millions and millions of end-of-life panels in an environmentally safe and effective manner while also repurposing these U.S. critical materials. The Small-Cap Spotlight Podcast was hosted by Water Tower’s Tim Gerdeman and...

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Written by Customer Service on February 11, 2026. Posted in Public Companies.

NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel’s Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts. Dr. Barone will share insights from Candel’s HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discussions focused on advancing biomarker-driven clinical development in glioblastoma. Details are as follows: Workshop Panel Title: Harnessing Omics...

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

Written by Customer Service on February 11, 2026. Posted in Public Companies.

Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it will attend the Society of Toxicology (“SOT”) meeting in San Diego, CA that takes place March 22-25 and present new data on its NAMkind™ liver and NAMkind™ Intestine model, including data on validating the models for use in predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). Considering the hundreds of ADCs in development across the globe, the potential for off target toxicity due to their common use in oncology to deliver...

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Written by Customer Service on February 11, 2026. Posted in Public Companies.

The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 financial results after the market close on Wednesday, February 25, 2026. Catalyst’s management team will host a conference call and webcast on Thursday, February 26, at 8:30 AM ET to discuss the Company’s financial results and provide a business update. Conference Call & Webcast DetailsDate: February 26, 2026Time: 8:30...

Edible Garden to Introduce Clean-Label JEALOUSY GLP-1 Support System and New Kick. Sports Nutrition® Innovations at ECRM Total Wellness Session

Written by Customer Service on February 11, 2026. Posted in Public Companies.

Expands Wellness Platform with Targeted GLP-1 Support Products Focused on Fiber, Vitality, and Protein Kick. Sports Nutrition® Expands with New Flavor Innovations Across Protein and Pre- and Post-Workout Lines BELVIDERE, NJ, Feb. 11, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced that it will debut JEALOUSY, a clean-label GLP-1 support system developed using the Company’s Farm to Formula® approach at ECRM’s Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session, taking place February 10–12, 2026, at the Hyatt Regency Chicago O’Hare in Rosemont, Illinois. The ECRM Total Wellness Session brings together leading...

Genvor’s AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™

Written by Customer Service on February 11, 2026. Posted in Public Companies.

Greenhouse trial results published jointly with USDA-ARS demonstrate 76-98% reduction in aflatoxin contamination in transgenic corn expressing the BioCypher-designed peptide AGM182 Woodland, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) — Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture’s Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. The publication, titled, “Transgenic...

Aveanna’s Heartways Program Receives CHAP Disease Program Certification

Written by Customer Service on February 11, 2026. Posted in Public Companies.

ATLANTA, Feb. 11, 2026 (GLOBE NEWSWIRE) — Community Health Accreditation Partner (CHAP), an independent, non-profit accrediting body for home and community-based healthcare, and Aveanna Healthcare (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care in the home, announced today that Aveanna Home Health and Hospice, a division of Aveanna Healthcare, has been awarded a Disease Program Certification for Heart Failure under the CHAP Disease Program Standards. CHAP certification demonstrates that Aveanna Home Health and Hospice meets the industry’s highest nationally recognized standards. CHAP’s rigorous program evaluation focuses on program structure and function, quality metrics, advanced education for clinicians, and demonstrated self-management tools for patients. “By achieving CHAP Disease Program...

Day: February 11, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals